Crescita Therapeutics Inc.
CTX.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 84.77% | -12.25% | -45.75% | -320.94% | 88.46% |
| Total Depreciation and Amortization | 13.94% | 2.97% | -22.20% | 2.51% | -0.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -52.77% | 51.05% | 208.76% | -141.53% | 188.26% |
| Change in Net Operating Assets | 6.14% | -5.60% | 53.47% | 203.74% | -169.09% |
| Cash from Operations | 216.18% | -22.22% | 42.55% | 246.19% | -305.79% |
| Capital Expenditure | 58.66% | 8.48% | -- | -- | -269.38% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 54.38% | 17.06% | -- | -- | -269.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.73% | 0.00% | -1.85% | -2.86% | -1.94% |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | 34.19% | -143.75% | 38.46% | 49.02% | 36.25% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -3.00% | -44.07% | 34.00% | 7.70% | 21.52% |
| Foreign Exchange rate Adjustments | 396.80% | -531.03% | -3.33% | 134.09% | -153.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 241.75% | -10.94% | -450.23% | 123.17% | -205.96% |